Transplantation, Organ
Conditions
Brief summary
The primary purpose is to describe the pattern of Belatacept use at the time of transplant and up to three years post-transplantation for all Belatacept treated patients.
Detailed description
Time Perspective: Prospective design, Retrospective data collection and analysis
Interventions
None listed
Sponsors
Heidelberg University
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who received solid organ transplantation during study period in one of the transplant centers involved in CTS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by Cytomegalovirus (CMV) serostatus | At the time of transplantation |
| The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus | 1 year post transplantation |
Secondary
| Measure | Time frame |
|---|---|
| Extent of switches to or from Belatacept within three years post transplantation, and the temporal trend in switches post regulatory approval of Belatacept | At transplantation, 12 month, 24 month and 36 month post transplantation |
| Characteristics of Belatacept users vs. Calcineurin inhibitor (CNIs) users at transplantation | At the time of transplantation |
| Characteristics of those who switch to or from Belatacept vs. those who do not switch one year post-transplant | At transplantation and 12 month post transplantation |
Outcome results
None listed